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Background: One of the major risk variables for surgical site infection is wound management. Understanding
infection risk factors for breast operations is essential in order to develop infection-prevention strategies and
improve surgical outcomes. The aim of this trial is to assess the influence of dressing wear time on surgical site
infection rates and skin colonization. Patients’ perception at self-assessment will also be analyzed.
Methods/Design: This is a two-arm randomized controlled trial. Two hundred breast cancer patients undergoing
immediate or delayed breast reconstruction will be prospectively enrolled. Patients will be randomly allocated to
group I (dressing removed on postoperative day one) or group II (dressing removed on postoperative day six).
Surgical site infections will be defined by standard criteria from the Centers for Disease Control and Prevention
(CDC). Skin colonization will be assessed by culture of samples collected at predefined time points. Patients will
score dressing wear time with regard to safety, comfort and convenience.
Discussion: The evidence to support dressing standards for breast surgery wounds is empiric and scarce. CDC
recommends protecting, with a sterile dressing for 24 to 48 hours postoperatively, a primarily closed incision, but
there is no recommendation to cover this kind of incision beyond 48 hours, or on the appropriate time to shower
or bathe with an uncovered incision. The results of the ongoing trial may support standard recommendations
regarding dressing wear time after breast reconstruction.
Trial registration: ClinicalTrials.gov identifier: NCT01148823.
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Surgical site infection (SSI) is a relevant problem in sur-
gical practice, with surrounding issues that still need to
be clarified [1-4]. Interventions to reduce the incidence
of SSI are essential to reduce not only morbidity, but
also costs to the individual and to society [2,5-7].
The infection risk for clean wounds is estimated to be
1 to 2% [8]. However, SSI rates following breast surgery
seem to be much higher than that expected for clean
surgical procedures and range from 1 to 30% in the lit-
erature [7,9-11]. Furthermore, SSI rates after breast* Correspondence: danifveiga@uol.com.br
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reproduction in any medium, provided the orcancer surgical procedures are more common than SSI
after non-cancer-related breast operations [7]. The in-
cidence in the literature of SSI after mastectomy varies
from 1% to 28% [5,12-14], and SSI rates after breast
reconstructive procedures range from 6.3% to 28%
[5,7,15-18].
Identifying SSI risk factors for breast surgery is essen-
tial in order to develop infection-prevention strategies
and improve surgical outcomes [7]. Risk factors for SSI
are usually classified into preoperative (patient-related,
for example, age, obesity, tobacco use, comorbidities,
use of immunosuppressive medications), perioperative
(procedure-related factors, such as type and duration of
the operation, hypoxia, operating room traffic and oper-
ating room parameters) and postoperative categories
[2,19]. One of the major risk factors in the postoperativetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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portance of surgical wound management in preventing
infection, literature on incisional wound management is
sparse [21,22].
Postoperative wound care is an ancient practice, with
recorded evidence dating back 4,000 years [23]. Purposes
for wound dressing include protection of the wound
from trauma and contamination, absorption of wound
exudates and compression to minimize edema and oblit-
erate dead space [23-27].
The search for an ideal postsurgical breast dressing
has led to the development of several different materials
and application techniques [28,29]. Despite the abun-
dance of wound dressing products available nowadays,
there is little empiric evidence to guide product choice
for site-specific incisional wounds [26,30], and trad-
itional low-technology gauze-based dressings are com-
monly used [25,27,29,31,32]. Due to lower costs, this
kind of dressing is largely used in the public health sys-
tem in Brazil.
From the literature, the ideal dressing wear time is also
controversial. Some authors recommend the early expos-
ure of the surgical wound, to allow easy wound inspec-
tion without inconvenience to the patient, to release the
patient for his/her routine personal care and to decrease
costs [21,22,24]. Other authors recommend the use of
dressings for a longer time, frequently until sutures are
removed, without increase in SSI rates [6,31,33,34].
The Centers for Disease Control and Prevention
(CDC) provide recommendations concerning prevention
of SSIs. No recommendation is offered for some
practices, either because there is a lack of consensus
regarding their efficacy or because the available scientific
evidence is insufficient to support their adoption [19].
Available evidence to support dressing standards for
incisional wounds, including breast surgery wounds,
is empiric and scarce [20,23,24,26,27,30,35]. CDC’s
guidelines instruct that wounds that are closed primarily
should be covered with a sterile dressing for 24 to 48 -
hours [19]. There is neither recommendation of the type
of dressing nor the ideal dressing wear time following
breast surgery. These remain unsolved issues, and
decisions regarding routine dressing are made on the
basis of surgeons’ personal experience [19].
This randomized controlled trial was designed to
assess the influence of dressing wear time after breast re-
construction on SSI rates, skin colonization and patients’
perceptions of safety, comfort and convenience.
Methods/Design
Study aims
To assess whether dressing wear time after breast recon-
struction will influence SSI rates. Secondary aims are
to assess the influence of dressing wear time on skincolonization and patients’ perceptions with regard to
safety, comfort and convenience.
Ethical issues
The Universidade do Vale do Sapucaí Ethical Committee
approved the study protocol (786/07 and 1623/11). Only
participants who have agreed to provide written in-
formed consent will be included in the study.
Study design and setting
This is a two-arm parallel group randomized controlled
trial, to be conducted in a university-affiliated hospital.
Patients will be recruited from the Breast Unit of the
Plastic Surgery Division of the Hospital das Clínicas
Samuel Libânio - Universidade do Vale do Sapucaí. This
trial was registered in ClinicalTrials.gov (NCT01148823).
Sample size
SSI rates following breast reconstruction vary in the lit-
erature, from 1% a 30% [1,4,5,9-11]. We considered
clinically relevant a 10% difference in SSI rate [35]. Spe-
cifying an acceptable Type 1 error of 5%, and Type 2
error of 20%, the estimated sample size was 100 patients
per arm.
Eligibility criteria
Inclusion criteria
Breast cancer patients over 18 years of age undergoing
immediate or delayed breast reduction at Hospital das
Clinicas Samuel Libânio will be considered eligible for
participation.
Exclusion criteria
Patients with body mass index (BMI) above 35Kg/m2,
those with usual contraindications for breast reconstruc-
tion procedures, such as diabetes or heavy smoking, will
be excluded. Patients whose dressings get wet in the first
24 hours after operation, thus requiring their change,
will also be excluded.
Groups’ assignment, randomization and allocation
concealment
Two hundred patients will be prospectively enrolled
after giving informed consent. Patients will be randomly
assigned to group I (n = 100), which will have dressings
removed on the first postoperative day or to group II
(n = 100), whose dressings will be removed on the sixth
postoperative day. The rationale for comparing 24
hours versus 144 hours of dressing include CDC
recommendation of protecting an incision with a sterile
dressing for 24 to 48 hours [19] (group I) and the time
of removing sutures (group II).
The allocation will be determined by a computer-genera-
ted sequence (Bioestat 5.0, Instituto de Desenvolvimento
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sealed opaque envelope will be opened on the first
postoperative day to reveal the group to which the patient is
allocated.Baseline procedures and interventions
Patients will take a shower with liquid detergent-based
chlorhexidine 4% prior to the operation [36], and an
alcoholic solution of chlorhexidine 0.5% will be used for
the antisepsis of the surgical site in the operating room
[37]. Patients will undergo immediate or delayed breast
reconstruction under general anesthesia, by the use of
flaps and/or implants and, performed by the same surgi-
cal team. All patients will receive prophylactic antibiotics
(cephazolin).
At the end of the operation, the surgical site will be
cleansed with sterile physiological saline, a sample for
quantitative skin culture will be obtained and a conven-
tional gauze and tape dressing, which use is the
established practice in our hospital, will be applied.
Sutured wounds will be completely covered with four
layers of dry sterile cotton gauze and fixed in place by a
microporous adhesive tape. The surgical team will not
be aware of the group to which the patient will be
allocated.
Patients allocated to group I will be instructed to keep
their wounds uncovered and to follow their usual per-
sonal hygiene routine, and patients in group II will be
instructed not to wet the dressing.
Quantitative skin cultures will be obtained in the oper-
ating room immediately before applying the dressing, as
well as immediately after the removal of dressing. In
group I, an additional sample will be collected at the
sixth postoperative day. A standard 5cm by 10 cm area
(determined by a sterile pattern) over the surgical wound
will be swabbed with a sterile cotton swab pre-
moistened with sterile saline. This swab will be placed in
a sterile container with 1.0 ml of saline and immediately
conducted to the laboratory.
Patients will be discharged from the hospital on the
first postoperative day after allocation, and they will re-
turn weekly for follow-up, for four weeks.Microbiological methods
Standard microbiological methods and criteria will be
used to identify microorganisms [38]. Aliquots of 0.2 ml
of the sample will be plated on hypertonic manitol (HM)
agar, selective for staphylococci; on blood agar, to iden-
tify hemolytic colonies; on Sabouraud agar with chlor-
amphenicol (0.05mg/ml), selective for fungi and yeasts;
and on eosin-methylene blue (EMB) agar, selective for
enterobacteria. The plates will be incubated aerobically
for 48 hours at 37°C. The same laboratory technicianwill process all samples and, after 48 hours, the plates
will be examined by a microbiologist.
Bacterial count results will be reported as colony
forming units (CFU) per plate. Whenever CFU count in
a plate exceeds 300, it will be scored as over 300.
Staphylococci will be identified as coagulase-negative
Staphylococcus sp. or S. aureus on the basis of Gram
stain, the presence of hemolysis and on coagulase
testing. The same microbiologist will assess all the
plates. Both the laboratory technician and the micro-
biologist will be blinded.
Assessment of postoperative infection
The Centers for Disease Control and Prevention (CDC)
considers SSI to be an infection that occurs within 30
days after the operative procedure if no implant is left in
place, or within one year if an implant is in place and
the infection appears to be related to the operative
procedure [39]. Thus, patients will be systemati-
cally followed-up once a week for 30 days regarding
postoperative infection, by a single surgeon. Patients
who receive an implant will have an additional assess-
ment by the same surgeon, one year after the operation.
The CDC definitions and classifications of SSI will be
considered (Table 1) [39]. As with all CDC definitions of
nosocomial infections, a surgeon’s diagnosis of infection
will be considered an acceptable criterion for an SSI
[39].
Patients’ assessments of dressing wear time
On their return in the second week after operation,
patients will be asked to rate their dressing wear time
with regard to safety, comfort and convenience, by the
use of a 5-point rating scale (Table 2) [35].
Outcomes measures
The primary outcome is the incidence of SSI, which will
be defined on the basis of CDC’s definitions [39]. Skin
colonization rates and patients’ preferences regarding
dressing wear time are secondary outcomes.
End points
Participation is considered complete after the 30th
postoperative assessment day if no implants have been
used, or after the 12th postoperative month if an implant
was used. Another exit point is if the dressings of group
II patients get wet before the sixth postoperative day,
thus requiring withdrawal from the study.
Statistical analysis
The rejection level for the null hypothesis will be fixed
at 5% (α ≤ 0.05). The Mann-Whitney test will be used to
compare groups I and II with regard to age, BMI and
duration of operation.
Table 1 CDC definitions of SSI [39]
Superficial incisional SSI Deep incisional SSI Organ/Space SSI
Involves only skin or subcutaneous tissue and
meets at least one of the following:
Involves deep soft tissues (fascial and muscle
layers) and meets at least one of the following:
Involves any part of the anatomy (organs or
spaces) and meets at least one of the following:
• Purulent drainage from the superficial incision; • Purulent drainage from the deep incision but
not from the organ/space component of the
surgical site;
• Purulent drainage from a drain that is placed
through a stab wound into the organ/space;
• Organisms isolated from an aseptically
obtained culture of fluid or tissue from the
superficial incision;
• A deep incision that spontaneously dehisces or
is deliberately opened by a surgeon when the
patient has at least one of the following signs
or symptoms: fever (>38°C), localized pain or
tenderness, unless the incision is culture-
negative;
• Organisms isolated from an aseptically
obtained culture of fluid or tissue in the organ/
space;
• At least one of the following signs or
symptoms of infection: pain or tenderness,
localized swelling, redness or heat, and the
superficial incision is deliberately opened by
surgeon unless the incision is culture-negative;
• An abscess or other evidence of infection
involving the deep incision is found on direct
examination, during reoperation, or by
histopathologic or radiologic examination;
• An abscess or other evidence of infection
involving the organ/space that is found on
direct examination, during reoperation, or by
histopathologic or radiologic examination;
• Diagnosis of superficial incisional SSI by the
surgeon or attending physician.
• Diagnosis of deep incisional SSI by the
surgeon or attending physician.
• Diagnosis of an organ/space SSI by the
surgeon or attending physician.
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II regarding SSI occurrence. Logistic regressions will
be applied to detect significant associations between
variables such as age, BMI and duration of operation
and the incidence of SSI.
For inter-group assessment of skin colonization, the
Mann-Whitney test will be used to compare groups I
and II pre-dressing and at the sixth postoperative day.
These tests will be applied independently for each
medium used. Because skin colonization could play a
role in SSI rates, an intra-group assessment of skin
colonization will also be performed. For this assessment,
in group I Friedman two-way analysis of variance will be
used to assess the differences in number of CFU among
the three moments (pre-dressing, first and sixth post-op-
erative day). Whenever the difference is significant, the
Friedman two-way analysis of variance will be com-
plemented by the multiple comparisons test to deter-
mine which moment significantly differed from the
others. In group II, the Wilcoxon test will be used toTable 2 Patients’ self-assessment of dressing wear time
Please rate the dressing wear time following your breast surgery in
regard to:
Safety
( ) Excellent ( ) Very good ( ) Good ( ) Fair ( ) Poor
Comfort
( ) Excellent ( ) Very good ( ) Good ( ) Fair ( ) Poor
Convenience
( ) Excellent ( ) Very good ( ) Good ( ) Fair ( ) Poor
Regardless of how many time your dressing was left in place, if you
had the choice, would you prefer to keep the dressing for one day or
for six days?
( ) 1 day ( ) 6 dayscompare the number of CFU pre-dressing and at the
sixth postoperative day.
The Kolgomorov-Smirnov test will be applied to com-
pare the two groups regarding patients’ assessments of
safety, comfort and convenience. The Fisher test will be
used to compare groups I and II regarding patients’
choice (one day or six days).
Statistical analysis will be performed using SPSS (Statis-
tical Package for Social Sciences, Inc., Chicago, IL, USA)
v.18 and Bioestat 5.0 (Instituto de Desenvolvimento
Sustentável Mamirauá, Belém, PA, Brazil).
Discussion
SSI is a major source of adverse events in patients under-
going breast cancer surgical procedures, generating psycho-
logical issues, increased duration of hospitalization and
costs, as well as delay in commencing postoperative adju-
vant therapies [2,5,11]. Consequently, surgeons should
make a determined effort to prevent SSI. As protocols and
guidelines should be founded on evidence-based medicine
principles, well-designed studies are essential to support or
to adjust clinical practice [20].
Wound management is a key area in preventing SSI
[21]. However, few studies have focused on the manage-
ment of the wound after closure as a method of redu-
cing infection [34]. This randomized trial focuses on the
influence of dressing wear time in SSI rates. Since the
greater the degree of surgical wound contamination, the
higher the risk for infection [2,19], skin colonization
assessment is a secondary aim of this study.
The management of surgical wounds should involve
the principle of minimizing harm, and patient preference
and tolerance must also be considered [30]. Thus,
assessment of patients’ perceptions of dressing wear time
is another secondary aim in this trial. Some authors
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postoperative hours could be convenient for patients,
allowing them to carry out their personal hygiene more
easily [24]. However, other authors observed that dres-
sings are comforting to patients by masking their scars
without increasing SSI rates [23,26,35]. Considering the
mutilating characteristics of breast cancer treatment, we
hypothesize that patients, particularly those who undergo
immediate breast reconstruction, might prefer to keep their
dressings in place for a longer time, thus delaying the mo-
ment of seeing their reconstructed breasts.
CDC’s guidelines for managing surgical wounds that
are closed primarily instruct patients to keep their
wounds dry and covered for 24 to 48 hours [19], but the
ideal dressing wear time following breast surgery re-
mains an unsolved issue. The results of this trial may
support standard recommendations regarding dressing
wear time after breast reconstruction.
Trial status
Recruitment is on-going (134 patients had been operated
on by the end of December 2012).
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